Second radiation blast shows promise for tough brain cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: 1. Histological diagnosis Previous histologic diagnosis of glioblastoma, transformation to glioblastoma or gliosarcoma established by biopsy or resection prior to enrollment as evident on NIH or outside pathology. 2. Patients must be age greater than or equal to 18. 3. Patients should have a KPS greater than or equal to 70% 4. Prior standard radiation therapy to a dose ranging from 50 to 60 Gy at 1.8 to 2 Gy per fraction. 5. Patients must be more than or equal to 14 days from previous cytotoxic treatment. 6. Concurrent therapy The concurrent use of bevacizumab is allowed if previously initiated for tumor progression or symptomatic management. Prior temozolomide or other cytotoxic chemotherapy is allowed. 7. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. 8. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. EXCLUSION CRITERIA: 1. Prior therapy \< than 2 weeks since surgical re-resection or biopsy 2. Pregnant or breast feeding females are excluded due to potential mutagenic effects on the developing fetus or newborn 3. Preexisting grade 3 or 4 nervous system disorder as per CTCAE Version 4.0 4. Clinically significant unrelated systemic illness (including but not limited to active life threatening infection, cardiac or neurologic events, current hospital admission for a coexisting comorbid illness), which would make it impossible for the patient to tolerate re-irradiation or systemic chemotherapy or likely to interfere with the results. 5. Patients exhibiting baseline grade 3 or 4 by CTCAE criteria are excluded due to difficulty in assigning these to the study intervention as treatment related DLT. 6. Patients with preexisting known or suspected radiation sensitivity syndromes will be excluded due to potential confounding effect on outcome.